These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23903848)

  • 1. Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.
    Davenport TM; Guttman M; Guo W; Cleveland B; Kahn M; Hu SL; Lee KK
    J Virol; 2013 Oct; 87(19):10855-73. PubMed ID: 23903848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
    Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
    J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.
    Yasmeen A; Ringe R; Derking R; Cupo A; Julien JP; Burton DR; Ward AB; Wilson IA; Sanders RW; Moore JP; Klasse PJ
    Retrovirology; 2014 May; 11():41. PubMed ID: 24884783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120.
    Guttman M; Kahn M; Garcia NK; Hu SL; Lee KK
    J Virol; 2012 Aug; 86(16):8750-64. PubMed ID: 22674993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity.
    Upadhyay C; Rao P; Behzadi MA; Feyznezhad R; Lambert GS; Kumar R; Kumar M; Yang W; Jiang X; Luo CC; Nadas A; Arthos J; Kong XP; Zhang H; Hioe CE; Duty JA
    Front Immunol; 2024; 15():1476924. PubMed ID: 39380992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.
    Liang Y; Guttman M; Davenport TM; Hu SL; Lee KK
    Biochemistry; 2016 Apr; 55(15):2197-213. PubMed ID: 27003615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States.
    Heredia JD; Park J; Choi H; Gill KS; Procko E
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.
    Leaman DP; Stano A; Chen Y; Zhang L; Zwick MB
    J Virol; 2021 Jun; 95(13):e0000521. PubMed ID: 33883221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural definition of a conserved neutralization epitope on HIV-1 gp120.
    Zhou T; Xu L; Dey B; Hessell AJ; Van Ryk D; Xiang SH; Yang X; Zhang MY; Zwick MB; Arthos J; Burton DR; Dimitrov DS; Sodroski J; Wyatt R; Nabel GJ; Kwong PD
    Nature; 2007 Feb; 445(7129):732-7. PubMed ID: 17301785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.
    Gift SK; Zentner IJ; Schön A; McFadden K; Umashankara M; Rajagopal S; Contarino M; Duffy C; Courter JR; Zhang MY; Gershoni JM; Cocklin S; Dimitrov DS; Smith AB; Freire E; Chaiken IM
    Biochemistry; 2011 Apr; 50(14):2756-68. PubMed ID: 21351734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity.
    Kong L; Sheppard NC; Stewart-Jones GBE; Robson CL; Chen H; Xu X; Krashias G; Bonomelli C; Scanlan CN; Kwong PD; Jeffs SA; Jones IM; Sattentau QJ
    J Mol Biol; 2010 Oct; 403(1):131-147. PubMed ID: 20800070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies.
    Chen W; Feng Y; Wang Y; Zhu Z; Dimitrov DS
    Biochem Biophys Res Commun; 2012 Sep; 425(4):931-7. PubMed ID: 22906742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
    Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
    J Virol; 2017 May; 91(9):. PubMed ID: 28202756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.